Proliferative breast disease: epidemiologic aspects, and cytologic diagnosis

Purpose: The aim of the present study is to describe the prevalence of proliferative breast lesions in cases of benign and malignant tumors of the breast as well as to assess the contribution of rapid intraoperative imprint cytology in the diagnosis of proliferative breast disease.

Methods: Frozen section and intraoperative imprint cytology were performed on breast tissue biopsies from 486 breast cancer patients who underwent primary surgical treatment. Imprints were stained either by the Papanicolaou (Pap) or the May Grünwald-Giemsa (MGG) or the Hematoxylin eosin (HE) technique. Cytologic diagnoses were compared to the histopathologic ones from paraffin sections.

Results: Sclerosing adenosis was the most common finding in benign breast biopsies while in breast cancer the prevalence of the lesion was reduced by half. On the other hand, atypical hyperplasias in malignant biopsies were almost twice as many as in benign ones. Imprint cytology presented high sensitivity and specificity (99% and 96% respectively) in distinguishing benign proliferative from malignant lesions as a whole, but regarding atypical hyperplasias the specificity was significantly reduced (76% vs 96%).

Conclusion: Clarification of cytologic diagnostic criteria and expertise in cytologic interpretation could show off intraoperative imprint cytology as a useful and inexpensive diagnostic tool providing the surgeon with prompt and accurate information regarding the nature of breast lesions.

Proliferative breast disease; Epidemiology; Imprint cytology; Sclerosing adenosis

[1] Lundin C., Mertens F.: "Cytogenetics of benign breast lesions" Breast Cancer Res. Treat., 1998, 51, 1.

[2] Consensus Statement by the Cancer Committee of the College of American Pathologists: Is "fibrocystic disease" of the breast precancerous? Arch. Pathol. Lab. Med., 1986, 110, 171.

[3] Runowicz C.: "Benign breast disease and screening for malignant tumors". In: Copeland L.J. (ed.): Textbook of Gynecology, Philadelphia: WB Saunders, 1993, 823.

[4] Dupont W.D., Page D.L.: "Risk factors for breast cancer m women with proliferative breast disease". N. Engl. J. Med., 1985, 312, 146.

[5] Simmons R., Osborne M.:'The evaluation of high risk and preinvasive breast lesions and the decision process for follow up and surgical intervention". Surg. Oneal., 1999, 8, 55.

[6] Dupont W.D., Parl F.F., Hartmann H., Brinton L.A., Winfield A.C., Worell A.J. et al.: "Breast cancer risk associated with proliferative breast disease and atypical hyperlasia". Cancer, 1993, 71, 1258.

[7] Marshall L.M., Hunter D.J., Connolly J.L., Schmitt S.J., Byrne C., London S.J. et al.: "Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types". Cancer Epidemiology Biomarkers and Prevention, 1997.

[8] Page D.L., Dalhany K.A., Jensen R.A., Dupont W.D.: "Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma". Cancer, 1996, 78, 258.

[9] Osborne M.P., Borgen P.L.: "Atypical ductal and lobular hyperplasia and breast cancer risk". Surg. Oneal. Clin. North. Arn., 1993, 2, 1.

[10] Rosai J.: "Borderline epithelial lesions of the breast". Arn. J. Surg Pathol., 1991, 15, 209.

[11]Schnitt S.J., Connolly J.L., Tavassolli F.A., F echner R.F., Kempson R.L., Golman R. et al.: " Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria". Arn. J. Surg. Pathol., 1992, 16, 1133.

[12] Cummings S., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A. et al.: "The effect of raloxifene on risk of breast cancer in postmenopausal women, results from the MORE randomized trial". JAMA, 1999, 281, 2189.

[13] F isher B., Costantino J., Wickerham D.L.:'Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study". J. Natl. Cancer Inst., 1998, 90, 1371.

[14] Koss L., Woyke S., Olszewski W.: "The breast". In: Koss L., Woyke S., Olszewski W., eds. "Aspiration biopsy: cytologic interpretation and histologic bases". New York: Igaku-Shoin Medical Publishers lnc., 1992, 141.

[15] Azavedo E., Svane G., Auer G.: "Stereotactic fine needle biopsy in 2594 mammographically detected non palpable lesions" Lancet, 1989, 1, 1033.

[16] Bardales R., Suhrland M., Stanley M.: "Papillary neoplasms of the breast: fine needle aspiration findings in cystic and solid cases". Diagn. Cytopathol., 1994,10, 336.

[17] Silverman J.: "Breast". In: Bibbo M. (ed.). Comprehensive Cytopathology. Philadelphia: WB Saunders, 1991, 703.

[18] Hughes LE., Mansel R.E., Webster D.J.T.: "Aberrations of normal development and involution (ANDI). A new perspective on pathogenesis and nomenclature of benign breast disorder". Lancet , 1987, 2, 1316.

[19] Bartow S., Pathak D., Black W., Key C., Teaf S.: "Prevalence of benign, atypical and malignant breast lesions in populations at different risk for breast cancer". Cancer, 1987, 60, 2751.

[20] Tinnemans J.G.M., Wobbs Th., Holland R., Hendriks J.H.C.L., van der Sluis R.F., Lubbers E.J.C. et al.: "Mammographic and histopathologic correlation on nonpalpable lesions of the breast and the reliability of frozen section diagnosis". Surg. Gynecol Obstet., 1987, 165, 523.

[21] Strickland L.B., Dawson P.J.: "The hyperplasia-to-carcmoma sequence in the breast. Immunohistochemical-histologic correlations". Appl. Immunohistochem. Molecul. Morphol., 2000, 8, 98.

[22] Mommers E., van Diest P., Leonhart A., Meijer C., Baak J.: "Balance of cell proliferation and apoptosis in breast carcinogen­esis". Breast Cancer Res. Treat., 1999, 58, 163.

[23] Anastasiadis P., Koutlaki N., Liberis V., Skaphida V., Tsikouras P., Galazios G.: "Cytologic diagnosis of axillary lymph node metas­tasis in breast cancer". Acta Cytol., 2000, 44, 18.